A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer Clinical Trial

Official title:

A Randomized, Open-label Phase Ib Trial of Fruquintinib "4mg Once Daily Continuous"Versus "5mg Once Daily 3wks on/1wk Off" in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01975077
• Other study ID #: 2012-013-00CH3
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 2012
• Est. completion date: October 2014

Study information

• Verified date: February 2019
• Source: Hutchison Medipharma Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study.

Description:

This is a phase Ib, randomize, interventional, open-label, multicenter study to provide fruquintinib to subjects diagnosed with metastatic colorectal cancer who have failed after standard therapy and for whom no therapy alternatives exist.

The primary endpoint of this study will be safety.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: October 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• = 18 and = 70 years of age , with = 40Kg

• Histological or cytological confirmed colorectal cancer

• ECOG performance status of 0-1

• Standard regimen failed or no standard regimen available

• Adequate hepatic, renal, heart, and hematologic functions

• At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

• Signed and dated informed consent.

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure

Exclusion Criteria:

• Pregnant or lactating women

• Any factors that influence the usage of oral administration

• Evidence of CNS metastasis

• Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure

• Abuse of alcohol or drugs

• Less than 4 weeks from the last clinical trial

• Previous treatment with VEGFR inhibition

• Disability of serious uncontrolled intercurrence infection

• Proteinuria = 2+ (1.0g/24hr)

• Uncontrolled hemorrhage in GI

• Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.

• Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG

• Bone fracture or wounds that was not cured for a long time

• Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• fruquintinib
Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong
China	Fudan University Cancer Center	Shanghai	Shanghai

Sponsors (3)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited	Fudan University, Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety and tolerability	The primary objective is evaluation of safety and tolerabilty with 2 regimens. The primary endpoint is the incidence of AEs, SAEs, Gr3/4 AEs and AEs led to dose interruption and dose discontinued	from day 1 of first dosing to 30days after permanent discontinuation of HMPL-013
Secondary	objective response rate(ORR)	using RECIST version 1.1	every 8 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
Secondary	pharmacokinetic profiles	At QD regimen, PK sampling will include a pre-dose and at the 1,2,4,8,24 hour time points on day 1 and day 21;a pre-dose and at the 2 hour time point on day 28,42,70,84.; At 3wks on/1wk off regimen,PK sampling will include a pre-dose and at the 1,2,4,8,24 hour time points on day 1 and day 21; a pre-dose and at the 2 hour time point on day 42 and day 70; only pre-dose on day 28,56,84.	Day 1-84 steady state
Secondary	disease control rate (DCR)	using RECIST version 1.1	every 8 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
Secondary	progression-free survival (PFS)	using RECIST version 1.1	every 8 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
Secondary	overall survival (OS)	from first dosing until death due to any cause, assessed up to 2 years	every 2 months since end of treatment